中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (25): 4711-4714.doi: 10.3969/j.issn.1673-8225.2011.25.037

• 生物材料学术探讨 biomaterial academic discussion • 上一篇    下一篇

缓释靶向模式的胃癌药物

苏晓晖1，李荣年2   

  1. 1辽宁省肿瘤医院，辽宁省沈阳市  110042
    2辽河油田中心医院普外二科，辽宁省盘锦市  124010
  • 收稿日期:2011-03-08 修回日期:2011-04-08 出版日期:2011-06-18 发布日期:2014-01-10
  • 作者简介:苏晓晖☆，男，1971年生，辽宁省沈阳市人，汉族，2009年中国医科大学毕业，博士，副主任医师，主要从事胃癌方面的研究。 zgh1975070707@163.com

Targeted and controlled-release gastric cancer drugs

Su Xiao-hui1, Li Rong-nian2   

  1. 1Liaoning Provincial Tumor Hospital, Shenyang  110042, Liaoning Province, China
    2Department of General Surgery, Central Hospital of Liaohe Oil Field, Panjin  124010, Liaoning Province, China
  • Received:2011-03-08 Revised:2011-04-08 Online:2011-06-18 Published:2014-01-10
  • About author:Su Xiao-hui☆, Department of General Surgery, Central Hospital of Liaohe Oil Field, Panjin 124010, Liaoning Province, China

PDF

333

被引次数

1

摘要：

背景：目前胃癌药物缓释靶向的研究已经取得了显著成果，但仍存在一些问题。
目的：总结近年胃癌药物缓释靶向模式的应用现状。
方法：应用计算机检索维普数据库中与胃癌药物缓释靶向模式有关的文章，检索时限1998-01/2010-10。检索关键词：胃癌，缓释，靶向，gastric cancer，delayed release，target。最终纳入符合标准的文献31篇。
结果与结论：目前对胃癌的淋巴靶向化疗研究较多，纳米炭在胃癌淋巴靶向化疗的应用已取得初步成果，应用前景令人鼓舞，有望成为胃癌淋巴靶向化疗的主要手段。但对如何选用合适的给药途径有待进一步研究，对如何联合用药、多途径用药和规范胃癌淋巴化疗的标准以及如何开展个体化治疗有待深入探索。胃癌药物的缓释靶向模式具有低毒高效性、功能性缓释特性以及良好的淋巴趋向性，可望有效抑制原发癌和淋巴结的转移率，缩小肿瘤，增加手术切除，降低术后复发和转移率，提高患者生存率和生活质量。

关键词: 胃癌, 缓释, 靶向, 药物载体, 生物材料

Abstract:

BACKGROUND: Currently, studies on targeted and controlled release of gastric cancer drugs have obtained an obvious progress, but there are still some problems.
OBJECTIVE: To conclude the application status of gastric cancer drugs in targeted and controlled release manners in recent years.
METHODS: A computer search of VIP database was performed for articles about targeted and controlled release of gastric cancer drugs published between January 1998 and October 2010. The keywords were “gastric cancer, delayed release, target” in Chinese and English. Finally, 31 articles were included in result analysis.
RESULTS AND CONCLUSION: Currently, there are many studies concerning lymphatic-targeted chemotherapy of gastric cancer, and nano-carbon used in lymphatic targeted chemotherapy in gastric cancer has obtained initial success, which is expected to become the primary means of lymphatic targeted chemotherapy for gastric cancer. How to select a proper administration approach is needed to be further studied as well as how to combine different drugs via multi-approaches and regulate chemotherapy standards for gastric cancer and how to develop individualized treatment. Targeted and controlled release gastric cancer drugs are characterized as low toxicity, functional release and good lymphatic tendency, which are expected to inhibit primary tumor incidence and lymp node metastasis, shrink the tumor, increase resection size, reduce the recurrence and metastasis, so as to improve patients’ survival rate and quality of life.

中图分类号: